|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
6
|
|
gptkbp:bfsParent
|
gptkb:Crysvita
|
|
gptkbp:acquisition
|
Gene Tx Biotherapeutics
Molecular Partners AG
Sangamo Therapeutics' gene therapy assets
|
|
gptkbp:ceo
|
Emil D. Kakkis
|
|
gptkbp:clinical_trial
|
gptkb:Europe
gptkb:Australia
gptkb:Japan
gptkb:United_States
gptkb:Native_American_tribe
Phase 1
Phase 2
Phase 3
Crysvita for X-linked hypophosphatemia
Mepsevii for mucopolysaccharidosis type VII
U X007 for long-chain fatty acid oxidation disorders
|
|
gptkbp:collaborations
|
gptkb:Stanford_University
gptkb:University_of_California,_San_Francisco
gptkb:Children's_Hospital_of_Philadelphia
|
|
gptkbp:employees
|
over 300
|
|
gptkbp:focus
|
rare diseases
|
|
gptkbp:founded
|
gptkb:2010
|
|
gptkbp:founder
|
Emil D. Kakkis
|
|
gptkbp:headquarters
|
gptkb:Novato,_California
|
|
gptkbp:healthcare
|
gptkb:Crysvita
Dojolvi
Mepsevii
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ultragenyx Pharmaceutical
|
|
gptkbp:investment
|
gptkb:Company
gptkb:Orbi_Med_Advisors
Perceptive Advisors
RA Capital Management
|
|
gptkbp:market_cap
|
$2 billion (2021)
|
|
gptkbp:partnership
|
gptkb:Bayer_AG
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:products
|
gptkb:Crysvita
Dojolvi
Mepsevii
U X003
U X005
U X006
U X007
U X202
U X701
|
|
gptkbp:research_focus
|
gptkb:physicist
small molecule therapy
|
|
gptkbp:revenue
|
$100 million (2020)
|
|
gptkbp:symbol
|
RARE
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:website
|
www.ultragenyx.com
|